A Randomized, Double-blind, Multi-center, Therapeutic Confirmatory, Phase 3 Trial to Evaluate the Efficacy and Safety of D150, D745 and D759 Combination Therapy in Pateints with Type 2 Diabetes Inadequately Controlled with D150 Plus D759
Latest Information Update: 13 Dec 2024
At a glance
- Drugs Lobeglitazone/D745/D150-Chong-Kun-Dang (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Chong Kun Dang
Most Recent Events
- 10 Dec 2024 Status changed from recruiting to completed.
- 06 Oct 2022 New trial record